"We'll pay more for the earnings of the non-Covid companies if The Lancet publishes some good news from AstraZeneca's vaccine trial," the "Mad Money" host said.
from US Top News and Analysis https://ift.tt/2OCStqJ "We'll pay more for the earnings of the non-Covid companies if The Lancet publishes some good news from AstraZeneca's vaccine trial," the "Mad Money" host said.
Cramer's week ahead: Big week for earnings, even bigger week for vaccines
0
July 18, 2020
July 18, 2020
